The employ of medical images combined with deep neural networks to assist in clinical diagnosis, therapeutic effect, and prognosis prediction is nowadays a hotspot. However, all the existing methods are designed based on the reconstructed medical images rather than the lossless raw data. Considering that medical images are intended for human eyes rather than the AI, we try to use raw data to predict the malignancy of pulmonary nodules and compared the predictive performance with CT. Experiments will prove the feasibility of diagnosis by CT raw data. We believe that the proposed method is promising to change the current medical diagnosis pipeline since it has the potential to free the radiologists.

开始日期2019-04-15

申办/合作机构

中国科学院

[+2]

100 项与东软医疗系统股份有限公司相关的临床结果

登录后查看更多信息

0 项与东软医疗系统股份有限公司相关的专利（医药）

登录后查看更多信息

项与东软医疗系统股份有限公司相关的文献（医药）

2025-09-01·NEUROIMAGE

Accelerating multi-directional diffusion MRI through patch-based joint reconstruction

Article

作者: Wang, Yaohui ; Chen, Zhifeng ; Liang, Xiaoyun ; Xu, Zhongbiao ; Cheng, Junying ; Guo, Li ; Deng, Guanhua ; Liu, Feng ; Zhang, Rongli ; Huang, Wei ; Chen, Zhaolin

Diffusion magnetic resonance imaging (dMRI) is a valuable technique for studying tissue microstructure and connectivity in the brain. However, acquiring high-resolution dMRI data is time-consuming, limiting its clinical applicability. Traditional parallel imaging techniques can accelerate the acquisition of dMRI, but they are constrained by the geometry factor. In this study, we propose a novel patch-based multiple diffusion directions joint reconstruction method that simultaneously capitalizes on the intra- and inter-image correlation across multiple diffusion directions by grouping similar 3D image patches and then enforces the sparsity of these groups in sensitivity encoding (SENSE) reconstruction, termed PB-SENSE. The simulation and in vivo experiments demonstrated that the proposed method can achieve high-quality images comparable to those obtained from fully sampled data, even with an acceleration of 5. This suggests that the proposed method has the potential to enhance the practical application of high-resolution diffusion imaging.

2025-08-01·Quantitative Imaging in Medicine and Surgery

Ultra-low-dose hepatic computed tomography with a novel real-time deep learning-based noise reduction algorithm: a prospective cross-sectional analysis of image quality and lesion detection

Article

作者: Feng, Xiangnan ; Xu, Chensi ; Chen, Yan ; Gao, Jianbo ; Zhou, Zhigang ; Jiang, Yaojun ; Liu, Jie ; Hou, Ping ; Lyu, Peijie ; Wang, Xiaopeng

Background:

Contrast-enhanced computed tomography (CT) is essential for tumor assessment, but the detection of low-contrast liver lesions remains challenging. Reducing the radiation dose increases image noise, compromising image quality and diagnostic accuracy. Iterative reconstruction (IR) algorithms can reduce noise; however, they can also alter image texture and limit lesion detection. Deep-learning image reconstruction (DLIR) represents a promising alternative, but its efficacy in ultra-low-dose (ULD) hepatic CT for detecting small, low-contrast lesions remains underexplored. Thus, this study aimed to evaluate a novel real-time DLIR algorithm in ULD hepatic CT, focusing on image quality and lesion detection.

Methods:

In total, 65 patients with hepatic lesions underwent both standard-dose and ULD abdominal CT scans during the portal venous phase. The standard-dose protocol (group A) used 120 kV with a signal-to-noise ratio (SNR) of 1.0, and the images were reconstructed using 50% IR. The ULD protocol (group B) used 120 kV with an SNR of 0.5, and the images were reconstructed using 50% IR and 50% DLIR (groups B1 and B2, respectively). The quantitative and qualitative image quality parameters were assessed. The lesion detection rates were evaluated by lesion type and size using the metrics of detection rate, sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV).

Results:

Group B showed a 73.3% reduction in the radiation dose compared to group A (1.5±0.8 vs. 6.9±2.0 mSv, P<0.001). Image noise differed significantly across the protocols: group B1 had the highest noise [10.05±2.94 Hounsfield units (HU)], followed by groups A (8.29±2.82 HU) and B2 (8.04±2.71 HU; all pairwise P<0.05 except group A vs. group B2: P=0.625). The CT values and contrast-to-noise ratios (CNRs) were comparable between groups B2 and A (all P>0.05), while group B2 had a 29.9-42.2% higher CNR than group B1 (all P<0.001). The qualitative assessments confirmed that the image quality and diagnostic acceptability of groups B2 (100%) and A (all P>0.05) were comparable, while the images of group B1 were diagnostically unacceptable (all scores <3). Overall, lesion detection was comparable in groups B2 (90.5%, 133/147) and A (98.0%, 144/147; P>0.05). However, group B2 had a significantly lower detection rate for small lesions (<0.5 cm: 77.8%, 42/54) compared to group A (P<0.05), but outperformed group B1 (57.4%, 31/54; P<0.05). Group B2 also had a significantly improved lesion detection rate and sensitivity for low-contrast lesions (87.2%, 95/109) compared to group B1 (75.2%, 82/109; P<0.05). The novel DLIR algorithm achieved a reconstruction speed of 60 images per second (ips), which was significantly faster than that of other DLIR approaches, while maintaining comparable performance to the IR algorithm.

Conclusions:

The combination of tube current reduction with a novel real-time DLIR algorithm enabled ULD abdominal CT to achieve a 73.3% reduction in the radiation dose while maintaining image quality and diagnostic performance for detecting hepatic lesions larger than 0.5 cm.

2025-08-01·Quantitative Imaging in Medicine and Surgery

Development and validation of a prognostic nomogram incorporating automated collateral score and computed tomography perfusion parameters for patients with acute ischemic stroke undergoing endovascular thrombectomy

Article

作者: Cheng, Yue ; Li, Yi ; Wu, Wenjuan ; Zuo, Qiang ; Wang, Ximing ; Ma, Jianing ; Fu, Lu ; Zhang, Lei

Background:

Prognostic evaluation of patients with acute ischemic stroke (AIS) after endovascular thrombectomy (EVT) remains challenging. Traditional computed tomography angiography (CTA) and computed tomography perfusion (CTP) have limitations, whereas multiphase CTA (mCTA) allows for more accurate collateral circulation assessment. However, the predictive utility of automated collateral scoring remains underexplored. This study aimed to develop and validate a nomogram combining automated collateral scores and CTP parameters to enhance the prognostic prediction in patients with AIS undergoing EVT.

Methods:

This retrospective study enrolled patients with AIS due to large-vessel occlusion (LVO) who underwent multimodal computed tomography (CT) and EVT between January 2017 and December 2022. The inclusion criteria were as follows: (I) age ≥18 years; (II) symptom onset within 24 hours; (III) available non-contrast CT (NCCT) and CTP; and (IV) 90-day modified Rankin Scale (mRS) score. Meanwhile, the exclusion criteria included posterior circulation stroke, intracranial hemorrhage, extensive prior infarction, prestroke mRS ≥2, poor image quality, and missing outcome data. A total of 111 patients were included and randomly assigned to development (n=77) and validation (n=34) cohorts. Clinical data, National Institutes of Health Stroke Scale (NIHSS) features, and imaging features [including automated collateral scores from NeuBrainCARE (NBC) software and relative cerebral blood flow (rCBF) <30% volume] were analyzed. Agreement between automated and manual Menon collateral scores was assessed via Cohen's kappa. A nomogram was constructed through multivariable logistic regression and validated with bootstrapping (500 iterations). Clinical outcomes were assessed at 90 days through the mRS, with outcomes categorized as good (mRS 0-2) or poor (mRS 3-6).

Results:

Manual collateral scoring between physicians showed substantial agreement (κ=0.667). For the automated scoring system, the consistency with manual scoring performed by a junior physician resulted in a kappa value of 0.597, while comparison with senior physicians yielded a higher kappa value of 0.872. The median age was 67 years [interquartile range (IQR), 54-74] years, and 60.3% were male. At 90 days, 54.1% had good outcomes (mRS 0-2). Key independent predictors included age, admission NIHSS, automated collateral score, and rCBF <30% volume (P<0.05). The nomogram achieved strong discrimination in both the development [concordance index (C-index) 0.872, sensitivity 82.9%, and specificity 80.6%] and validation (C-index 0.807, sensitivity 68.4%, and specificity 93.3%) cohorts.

Conclusions:

This study supports the use of automated collateral scoring as a reliable and unbiased method in AIS prognosis. The proposed nomogram, integrating clinical and imaging parameters, provides an effective tool for outcome prediction after EVT, facilitating individualized treatment planning and optimizing patient selection.

104

项与东软医疗系统股份有限公司相关的新闻（医药）

2025-08-29

·医药投资部落

创新药之后，下一个潜在的市场爆点

在2025年的创新药行情，如烈火烹油，整个板块积累了4年的势能与激情，集中在这个夏天彻底爆发。相比之下，同属于大健康方向的医疗器械板块，在2025年就显得有稍许的落寞。个中原因，在于医疗器械板块的内在逻辑迥异于创新药板块，二者出现各自独立的发展轨迹，也在情理之中。相比于创新药行业的管线对外BD做得飞起，已经跃迁为整个国民经济体系中重要的创汇部门之一，医疗器械板块还在为解决诸如医院预算约束、渠道去库存、DRG/DIP挤压支付空间等问题而奔忙。但是天下没有永远上涨的板块，也没有永远不涨的板块。这一轮创新药行业的大行情，其底层逻辑是中国创新药企业在研管线的创新，得到了来自全球头部药企和国际资本的认可。这种“认可”，绝非简单的恭维和客套，其表达方式是动辄以数亿美元计算的真金白银。对于中国医疗器械产业来说，在略显平静的行情之下，也在孕育着由底层创新驱动的长期爆发点。 2025年7月3日，国家药监局发布《关于发布优化全生命周期监管支持高端医疗器械创新发展有关举措的公告（2025年第63号）》。公告提出10条举措，全力支持高端医疗器械（医用机器人、高端医学影像设备、人工智能医疗器械和新型生物材料医疗器械等）重大创新，促进更多新技术、新材料、新工艺和新方法应用于医疗健康领域。支持性配套政策的出台，是与行业发展的节奏高度吻合的，中国医疗器械行业的硬核创新正在涌现。就在今年8月，A股上市公司东软集团自主研发的NeuViz P10碲锌镉光子计数CT，正式获得国家药品监督管理局（NMPA）批准上市。这不仅是中国首台光子计数CT，也是全球首台8cm宽体光子计数CT，这是中国高端医疗装备产业在一个细分领域的重大突破。国产创新药授权出海，已经成为行业常态，而在中国医疗器械领域，类似的案例也正在出现。 2025年4月，专注为听力障碍人士提供解决方案的中国公司声佗医疗宣布，与MED-EL旗下BHM公司达成了战略合作。声佗医疗将研发的两款创新骨传导听力产品的商业化许可（除中国以外市场），授权给BHM公司，由BHM公司及其母公司MED-EL进行推广和销售。 MED-EL是一家全球植入式听力设备领域的巨头公司，拥有覆盖超过130个国家的营销网络。一家细分领域的全球头部公司，从一家中国企业引进产品和技术，这是此前在医疗器械领域内相对罕见的现象。种种迹象表明，中国医疗器械行业正处于创新质变的临界点。今年以来，国家局已批准创新医疗器械产品52个，截至目前，累计批准创新产品367个。这些在各自领域取得突破性进展的创新医疗器械，其中蕴含着未来的商业化爆发机会。与此同时，国产医疗器械的出海进程，虽然没有创新药出海那样的巨大声势，但是其实已经取得了相当实质性的业绩。 2025年8月，国产医疗器械龙头迈瑞医疗发布半年报，其国际业务收入占公司整体收入的比重，已经提升至约50%，且在国内市场暂时低迷的情况下，国际业务收入仍然保持增长趋势。类似的海外收入占比超过50%的国产医疗器械企业，不止迈瑞医疗一家。以另一家科创板上市的医疗器械企业南微医学为例，其2025年上半年海外营收占比已攀至总收入的58%。从地区情况看，南微医学的收入分布很均匀：亚太区域营收8.08亿元，美洲区域营收3.41亿元，欧洲、中东及非洲区域营收4.16亿元（含CME）。当大部分创新药企业还在以管线BD作为主要的海外收入来源的时候，相当一批中国医疗器械企业，已经扎扎实实地做出了海外销售收入。对于这种基本面上的势能聚积，资本市场对此也开始有初步的反馈。从2025年2季度以来，医疗器械板块的行情也出现了复苏迹象。以医疗器械ETF（562600）为例，根据“红色火箭”的信息显示，最近4个月的最高涨幅已经触及20%，细节信息可以在这个小程序中看到（这个“红色火箭”小程序是查行情和看信息的一个便捷工具，对于热点信息的覆盖度很全）。医疗器械ETF（562600）追踪中证全指医疗器械指数，选取100支覆盖医疗器械、医疗服务、医疗信息化等领域的代表性上市公司证券作为样本。从行业结构看，该指数医疗器械行业占比高达89.34%，集中度突出，可以有效地捕捉医疗器械行业的走势。风险提示：本文仅作为业余研究学习与观点探讨之用，不构成任何投资建议。

引进/卖出上市批准

2025-08-27

·PRNewswire

Neusoft Medical Systems Launches China's First Photon-Counting CT with NMPA Approval

SHENYANG, China, Aug. 27, 2025 /PRNewswire/ -- Neusoft Medical Systems today announced that its NeuViz P10 photon-counting CT has received market approval from China's National Medical Products Administration (NMPA). This marks the first photon‑counting CT approved in China, and the world's first wide‑body system equipped with an 8‑cm detector. Continue Reading Neusoft Medical Systems Launches China’s First Photon-Counting CT with NMPA Approval Photon-counting CT (PCCT) is considered a breakthrough in next‑generation imaging. Unlike conventional CT scanners, which first convert X‑rays into light before generating digital images, the NeuViz P10 uses a cadmium zinc telluride (CZT) detector to capture and convert each X‑ray photon directly into a digital signal. This direct approach delivers images with far greater clarity, reduces radiation exposure for patients, and improves the ability to distinguish between different types of tissue. For patients, these advances mean clearer visualization of tiny blood vessels in the heart, earlier detection of small tumors, more accurate identification of neurological conditions, and safer lung examinations with reduced exposure to radiation. The system's ultra-high resolution also helps doctors detect diseases at earlier stages, when treatment can be more effective and outcomes significantly improved. To maximize clinical and research value, the NeuViz P10 integrates four innovation platforms: NeuPhoton Counting, Photon Supersonic, Photon Intelligence, and Photon Research. Together, these platforms deliver faster scans, safer imaging, intelligent workflow support, and expanded opportunities for clinical research. "The approval of NeuViz P10 is a milestone for China's medical imaging industry and for global CT innovation," said Patrick Wu, CEO of Neusoft Medical Systems. "This technology empowers radiologists with clearer images at lower doses, giving patients earlier and more accurate answers while delivering maximum clinical value for public health." About Neusoft Medical Systems Neusoft Medical Systems is a global leader in medical imaging solutions and services. The company is dedicated to integrating AI technologies with medical imaging to deliver intelligent, efficient, precise, and reliable products and services. By building a comprehensive healthcare ecosystem, Neusoft Medical Systems enhances the accessibility and equity of global healthcare. By the end of 2024, Neusoft Medical Systems had a presence in over 120 countries and regions, serving more than 14,000 customers, with a historical installed base exceeding 50,000 units. Learn more about us: SOURCE Neusoft Medical Systems Co., Ltd. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

放射疗法

2025-08-26

·医药健闻

和黄医药CEO换人；百济神州8.85亿美元出售新药特许使用权；泰尔茂将斥资约15亿美元收购OrganOx | 日报

全球医疗行业每日重点资讯文 | 苏丁企业动态和黄医药公告，董事会获悉公司执行董事苏慰国因健康理由将暂停履行首席执行官的职务。有鉴于此，董事会已委任公司执行董事兼首席财务官郑泽锋担任代理首席执行官一职，即时生效。联影集团已签约在武汉光谷建设全球创新高端医疗装备智造基地。这是联影落户湖北12年后的一次重量级追投。这一高端医疗装备智造基地将建设六大项目：外科诊疗装备整机与核心部件攻关与产业化基地项目；精密科学仪器国产化产业基地项目；医疗智能体与元医院数智化场景研发基地项目。自2013年重仓湖北、在光谷设立武汉总部以来，联影已累计投入超70亿元，其中研发投入超50亿元。西门子医疗与韩国庆尚北道浦项市达成一项合作。西门子医疗计划在2026年至2027年间，向浦项科技园投入210亿韩元（约合人民币1.08亿元），用于在9800平方米的园区内扩建超声心动图的生产设施。该扩建项目完成后，西门子医疗的超声心动图设备年产能预计将从目前的50万台提升至100万台，并新增超过400个就业岗位。赛默飞世尔科技（Thermo Fisher Scientific）启用位于北卡罗来纳州的一家高度自动化的制造工厂。该工厂占地37.5万平方英尺，每周可生产超过4000万个移液器吸头。该公司表示，位于梅班（Mebane）的该工厂每12秒可生产96个吸头，每小时可生产5000个成品组件。该工厂还配备了自动化的包装和运输设备。预计该工厂将提供约100个工作岗位，涵盖生产、工程和业务运营，目前已聘用了约40人。诺和诺德迎来一项重磅人事任命。Filip K. Knop已正式出任高级副总裁，并同时担任新成立的医学与转化科学（M&TS）部门负责人。此外，他将从10月1日起接过公司首席医疗官的接力棒，接替即将退休的Stephen Gough，开启在诺和诺德的全新征程。日本医疗器械生产商泰尔茂(Terumo)已同意以约15亿美元收购英国器官保存设备生产商OrganOx有限公司。此项收购将增强泰尔茂在器官保存技术领域的能力，标志着其战略性进入器官移植领域。吉利德科学公司（Gilead Sciences）以3.5亿美元收购了CAR-T疗法开发商Interius BioTherapeutics。将Interius整合入吉利德专注于细胞疗法的子公司Kite，为该制药公司提供一个体内平台，旨在在患者体内生成CAR-T细胞。Kite称，此举旨在“通过将DNA插入患者基因组，提供更持久和长效的治疗效果”。吉利德已获批的两款CAR-T疗法，均为传统体外疗法。相比之下，Interius的创新型即用型且个性化方案旨在通过单次静脉输注给药，无需预处理化疗和复杂的细胞处理流程。聚焦实体瘤耐药治疗的创新药研发公司应世生物InxMed Limited宣布完成超3400万美元的C轮融资，本轮融资由复健资本领投，比邻星创投、澄翔资本、昆仑资本投资，老股东恩然创投继续追加投资。信华生物药业（广州）有限公司完成数千万美元A+轮系列融资，杏泽资本领投。资金将主要用于推动公司核心管线进入全球临床试验阶段，加速首创新药（FIC）和同类最佳药（BIC）的研发进程。南京迈诺威医药完成亿元级B轮融资，由知名投资机构IDG资本独家领投，老股东元禾原点持续跟投。本轮融资将重点用于加速创新药研发管线推进，以及旗下核心产品 “蓉芷” 溶脂针剂的市场推广与销售布局。蚂蚁集团与北京大学第三医院达成战略合作，正式成立AI医疗联合创新实验室，将整合双方临床诊疗与专业大模型方面的优势，在多个科室内，开展医疗多模态大模型、人工智能辅助临床诊疗等技术研发与应用研究，推动AI医疗应用落地。迪哲医药发布2025半年报。报告期内，公司实现营业收入3.55亿元，较上年度同比增长74.4%。公司净亏损持续缩窄，同比下降12%。公司账上现金及现金等价物达22.51亿元。沛嘉医疗发布截至2025年6月30日止六个月的中期业绩。报告期内，本集团实现总收入人民币3.53亿元，较2024年同期增长17.3%。集团整体经营亏损收窄19.4%，为人民币6832万元。若剔除前沿技术业务相应实体整体亏损的影响，本集团期内核心业务净亏损为人民币3072万元，同比大幅收窄52.4%。深圳微芯生物科技股份有限公司发布2025年半年度报告：上半年营收4.07亿元，同比增速提升至34.56%；归属于上市公司股东的净利润2959.22万元，业绩扭亏为盈。复宏汉霖发布2025年中期业绩，公司2025上半年实现营收28.195亿元人民币，同比增长2.7%；净利润3.901亿元，经营性现金流超7.709亿元，同比增长206.8%，持续正向流入。产业动态百济神州公告称，公司及其全资子公司百济神州瑞士与RoyaltyPharma签订《特许权使用费购买协议》，RoyaltyPharma同意在交割时支付8.85亿美元，购买百济神州瑞士就单克隆抗体Imdelltra（Tarlatamab）在中国以外地区年度销售净收入收取中个位数百分比特许权使用费的大部分权利。此外，百济神州瑞士有权在2026年8月25日前出售额外的收取特许权使用费的权利，最高可获6500万美元额外付款。艾伯维同意以高达12亿美元的价格收购Gilgamesh Pharmaceuticals旗下一款实验性抗抑郁治疗药物。根据协议条款，艾伯维将收购Gilgamesh的核心候选药物bretisilocin，该药物正在开发用于治疗重度抑郁症。同时，Gilgamesh将把其其他研发项目剥离，组建一家新的实体公司—— Gilgamesh Pharma Inc.。 Jazz Pharmaceuticals与Saniona宣布，两家公司已达成全球许可协议，后者将授予Jazz对SAN2355的全球独家开发权。SAN2355是一种具有差异性的钾通道激活剂，主要用于癫痫及其他潜在适应症的开发，旨在克服非选择性Kv7靶向化合物的局限性。根据协议条款，Jazz将负责主导并资助SAN2355的进一步开发、监管申报及全球商业化活动。Jazz将预先支付4250万美元，并有望支付高达1.925亿美元的开发和监管里程碑款项。此外，Saniona还有资格获得高达8亿美元的商业里程碑款项，以及从个位数到两位数不等的净销售额分级特许权使用费，总计约10亿美元。由东软集团旗下的创新公司东软医疗，自主研发的NeuViz P10碲锌镉光子计数CT正式获得国家药品监督管理局（NMPA）批准上市。这不仅是中国首台光子计数CT，也是全球首台8cm宽体光子计数CT。信达生物宣布其自主研发的全球首创PD-1/IL-2α-bias双特异性抗体融合蛋白IBI363的首个全球III期临床研究（MarsLight-11）的新药临床试验申请（IND）获美国食品药品监督管理局（FDA）批准，用于治疗免疫耐药的鳞状非小细胞肺癌（NSCLC）患者，标志着这一创新性双免疫疗法的全球开发取得重要进展。由晨泰医药支持，中国肺癌领域权威专家吴一龙教授牵头开展的“佐利替尼真实世界研究者会暨肺癌脑转移高峰论坛”在广州召开。会上宣布，全球首个针对EGFR阳性伴脑转移非小细胞肺癌（NSCLC）患者的多中心前瞻性真实世界研究（RWS）正式启动。佐利替尼真实世界研究，采用创新的“以患者为中心”研究设计，预计纳入800例患者，覆盖全国多家顶尖医疗中心，旨在为肺癌脑转移诊疗提供高级别真实世界证据，推动临床实践优化。 NMPA官网显示，轩竹生物/先声药业1类新药地罗阿克获批上市，单药适用于未经过间变性淋巴瘤激酶（ALK）抑制剂治疗的 ALK 阳性的局部晚期或转移性非小细胞肺癌（NSCLC）患者的治疗。联系美通社 +86-10-5953 9500 info@prnasia.com

并购细胞疗法免疫疗法高管变更

100 项与东软医疗系统股份有限公司相关的药物交易

登录后查看更多信息

100 项与东软医疗系统股份有限公司相关的转化医学

登录后查看更多信息